GH Research PLC (GHRS)

Currency in USD
12.15
-0.91(-6.97%)
Closed·
After Hours
12.23+0.08(+0.66%)
·
GHRS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 14 days
GHRS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
11.8813.15
52 wk Range
6.0020.50
Key Statistics
Prev. Close
13.06
Open
12.99
Day's Range
11.88-13.15
52 wk Range
6-20.5
Volume
414.22K
Average Volume (3m)
244.79K
1-Year Change
14.06%
Book Value / Share
5
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GHRS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
33.14
Upside
+172.78%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

GH Research PLC News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

GH Research PLC Company Profile

GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression. The company also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Compare GHRS to Peers and Sector

Metrics to compare
GHRS
Peers
Sector
Relationship
P/E Ratio
−17.9x−0.5x−0.5x
PEG Ratio
0.72−0.010.00
Price/Book
2.4x2.8x2.6x
Price / LTM Sales
-1.8x3.3x
Upside (Analyst Target)
145.0%131.3%42.8%
Fair Value Upside
Unlock22.3%6.5%Unlock

Analyst Ratings

8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 33.14
(+172.78% Upside)

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-0.19 / -0.35
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

GHRS Income Statement

People Also Watch

0.989
GAME
+13.86%
4.190
ATAI
+1.21%
1.890
IPA
+4.42%
22.97
OUST
-4.45%
2.450
CRDF
-4.67%

FAQ

What Stock Exchange Does GH Research Trade On?

GH Research is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for GH Research?

The stock symbol for GH Research is "GHRS."

What Is the GH Research Market Cap?

As of today, GH Research market cap is 747.44M.

What Is GH Research's Earnings Per Share (TTM)?

The GH Research EPS (TTM) is -0.79.

When Is the Next GH Research Earnings Date?

GH Research will release its next earnings report on 19 Aug 2025.

From a Technical Analysis Perspective, Is GHRS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has GH Research Stock Split?

GH Research has split 0 times.

How Many Employees Does GH Research Have?

GH Research has 50 employees.

What is the current trading status of GH Research (GHRS)?

As of 06 Aug 2025, GH Research (GHRS) is trading at a price of 12.15, with a previous close of 13.06. The stock has fluctuated within a day range of 11.88 to 13.15, while its 52-week range spans from 6.00 to 20.50.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.